Comparative Pharmacology
Head-to-head clinical analysis: ATENOLOL versus INDERAL.
Head-to-head clinical analysis: ATENOLOL versus INDERAL.
ATENOLOL vs INDERAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective beta-1 adrenergic receptor antagonist; reduces heart rate, myocardial contractility, and blood pressure by blocking catecholamine effects.
Nonselective beta-adrenergic receptor antagonist; competes with catecholamines for binding at beta-1 and beta-2 receptors, decreasing heart rate, myocardial contractility, and blood pressure.
50 mg orally once daily; may increase to 100 mg orally once daily if needed.
Hypertension: 40 mg orally twice daily; increase as needed up to 640 mg/day. Angina: 80-320 mg orally daily in divided doses. Migraine prophylaxis: 80 mg orally daily in divided doses; up to 160-240 mg/day. Arrhythmias: 10-30 mg orally 3-4 times daily. IV: 1-3 mg IV bolus at 1 mg/min; may repeat after 2 min.
None Documented
None Documented
Clinical Note
moderateAtenolol + Digoxin
"Atenolol may increase the bradycardic activities of Digoxin."
Clinical Note
moderateAtenolol + Digitoxin
"Atenolol may increase the bradycardic activities of Digitoxin."
Clinical Note
moderateAtenolol + Deslanoside
"Atenolol may increase the bradycardic activities of Deslanoside."
Clinical Note
moderateAtenolol + Acetyldigitoxin
"Atenolol may increase the bradycardic activities of Acetyldigitoxin."
6-9 hours (terminal elimination half-life); may increase to 15-30 hours in renal impairment (CrCl <35 mL/min).
3-6 hours (terminal). Clinical context: half-life increases with chronic dosing due to saturable hepatic metabolism; in cirrhosis, half-life may be prolonged to 10-23 hours.
Renal: 40-50% unchanged drug; minor hepatic metabolism (10-20%) with biliary excretion of metabolites; <5% fecal.
Renal: 96-99% as metabolites (active 4-hydroxypropranolol and conjugates), <1% unchanged. Biliary/fecal: minimal.
Category C
Category C
Beta-Blocker
Beta-Blocker